Summary
The provided claims are about discounts, coupons, free trial/Starter Programs, pharmacy chain availability, and eligibility for savings programs. The supplied FDA label excerpts do not address patient savings programs, pricing, coupon cards, eligibility requirements, or specific discount amounts; therefore, label alignment cannot be verified and the content is unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Discounts for Vascepa (icosapent ethyl) are available at many U.S. pharmacies through manufacturer coupons, patient assistance programs, and free trial offers.
The supplied FDA label excerpts contain no information about manufacturer coupons, patient assistance programs, free trial offers, or availability at specific pharmacies.
Discounts can reduce Vascepa costs from around $300–$400 per month (cash price) to as low as $9–$10 per fill for eligible patients.
The supplied FDA label excerpts contain no pricing or cost-reduction figures, cash price ranges, or per-fill amounts.
A Vascepa Savings Card provides up to $150 off per 30-day supply for commercially insured patients.
The supplied FDA label excerpts contain no information about savings cards or dollar-off amounts.
The Vascepa Savings Card has a maximum annual savings of $1,800.
The supplied FDA label excerpts contain no information about savings card annual maximums.
The Vascepa Savings Card is valid at major chains like CVS, Walgreens, Walmart, and Rite Aid.
The supplied FDA label excerpts contain no information about where a savings card is accepted.
No income restrictions apply for the Vascepa Savings Card.
The supplied FDA label excerpts contain no information about eligibility criteria (including income restrictions) for any savings card.
Government insurance users (Medicare/Medicaid) are ineligible for the Vascepa Savings Card.
The supplied FDA label excerpts contain no information about Medicare/Medicaid eligibility for any savings card.
A Vascepa Starter Program provides new patients a free 30- or 90-day supply.
The supplied FDA label excerpts contain no information about Starter Programs or free trial/free supply durations.
Eligibility for the Vascepa Starter Program requires a prescription and no prior use in the last 90 days.
The supplied FDA label excerpts contain no eligibility criteria for any Starter Program.
The Vascepa Starter Program requires pharmacy processing directly.
The supplied FDA label excerpts contain no information about how any Starter Program is processed.
Medicare patients can be limited to patient assistance programs such as the Vascepa Patient Assistance Program.
The supplied FDA label excerpts contain no information about patient assistance programs or restrictions for Medicare patients.
The Vascepa Patient Assistance Program is income-based and provides free medication for those under 400–500% of the federal poverty level.
The supplied FDA label excerpts contain no information about income-based thresholds or free medication provisions.
Exclusions for Vascepa patient support include some state restrictions and non-U.S. pharmacies.
The supplied FDA label excerpts contain no information about state restrictions, exclusions, or non-U.S. pharmacy participation.
GoodRx coupons often reduce Vascepa copays compared with insurance.
The supplied FDA label excerpts contain no mention of GoodRx or third-party coupon programs.
GoodRx discounts can bring a 120-capsule (30-day) supply of Vascepa to $250–$300.
The supplied FDA label excerpts contain no pricing information or third-party coupon price estimates.
SingleCare and RxSaver offer similar deals for Vascepa, sometimes stacking with pharmacy loyalty programs.
The supplied FDA label excerpts contain no mention of SingleCare, RxSaver, or stacking with loyalty programs.
Vascepa cash prices for 120 capsules are stated as $298 at Walmart, $350 at CVS, and $370 at Walgreens.
The supplied FDA label excerpts contain no pharmacy-specific cash price data.
Vascepa key patents are described as expiring in 2035–2039.
The supplied FDA label excerpts contain no information about patents or patent expiration dates.
No generics for Vascepa have been approved yet.
The supplied FDA label excerpts contain no information about generic approval status.
Contradictions
Important Omissions
If the purpose was to provide prescribing-relevant information (e.g., indications, dosing, contraindications, warnings/precautions, interactions, or adverse reactions), none of those label elements were included in the provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims focus on cost/discount programs and do not directly assert clinical contraindications, dosing, or safety outcomes. However, because the statements are unsupported by the supplied prescribing information, they should not be treated as label-verified information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All provided claims are about pricing/coupon/patient support program details and generic/patent status, none of which are addressed in the supplied FDA label excerpts.
Suggested Improvement
Limit claims to information supported by the FDA-approved prescribing information (e.g., indicated uses, dosing instructions, contraindications, warnings/precautions, adverse reactions, and approved monitoring). If savings program details are needed, use sources explicitly authorized or documented by the program, and do not present them as FDA-label facts.